In the company’s news yesterday,
RXi Pharmaceuticals, in which CytRx Corporation holds a 45% stake, has signed an agreement with the University of Massachusetts Medical School for an exclusive worldwide license to certain technology for the oral delivery of RNAi therapeutics. RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases. This new agreement expands the delivery options and aids in delivery of RNAi therapies.
For those of you who are unfamiliar with RNAi, it is a naturally occurring mechanism for the regulation of gene expression that has the potential to be harnessed to selectively inhibit the activity of any human gene. It is believed that this inhibition may potentially treat human diseases by “turning-off” genes that lead to disease. Basically it’s like creating drugs specifically for YOU. We all know that everyone has different interactions with drugs. But now with drugs catered for RNAi, those problems can be overcome.
Tod Woolf, Ph.D., President and Chief Executive Officer of RXi Pharmaceuticals, commented, “The development of technology that potentially enables oral delivery represents a truly dramatic advance for the field of RNAi therapeutics, and could open up significant market opportunities for RXi. We view this license as a major step toward our goal of developing such drugs as it allows us to potentially target a new class of cells that cannot be accessed either by traditional RNAi delivery methods, local administration or injection. Since some of the most advanced and successful anti-inflammatory drugs currently on the market require injection, an orally administered RNAi compound could have significant competitive advantages for both patients and physicians.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
